Israel Englander’s Solid Biosciences SLDB Stock Holding History

Israel Englander’s Portfolio SLDB Stock Details SLDB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-7,433	Closed	-$617K	–	7053
2021 Q1	$617K	Sell	7,433 -2,747	-27%	-$304K	﹤0.01%	4646
2020 Q4	$1.16M	Buy	+10,180	New	+$644K	﹤0.01%	3638

Other funds holding SLDB

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Israel Englander's SLDB Position: Q2 2026 in Review

Israel Englander sold out of Solid Biosciences (SLDB) in Q2 2026, closing a stake of 363,675 shares — an estimated $2.62M sold.

Israel Englander first reported a position in SLDB in Q1 2018 and held it in 26 quarters. The position peaked at $9.8M in Q2 2024. 155 funds tracked by Wall St. Rank hold SLDB as of Q2 2026.

Israel Englander reported no remaining Solid Biosciences position as of Q2 2026 after selling out during the quarter.
Israel Englander sold 363,675 Solid Biosciences shares in Q2 2026, an estimated $2.62M.
Israel Englander first reported a position in Solid Biosciences in Q1 2018 and held it in 26 quarters.
Israel Englander's Solid Biosciences position peaked at $9.8M in Q2 2024.
155 funds tracked by Wall St. Rank held Solid Biosciences as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.